More than 80% of the population has significant back pain at some point in their life, with 30% of adults in the United States stating they have chronic low back pain at any given time; 5% of whom have inflammatory back pain. Axial spondyloarthritis (axSpA) affects almost 1.5% of patients with inflammatory back pain; however, the majority of individuals suffering with back pain are not being treated by a rheumatologist, which only exacerbates the challenge to diagnose those with axSpA.
In this subway themed activity, Dr. Leonard Calabrese discusses both radiographic and nonradiographic ankylosing spondylitis in detail, differentiating their diagnostic properties and how to properly treat and manage patients with this inflammatory disease that affects daily function and quality of life. Dr. Calabrese emphasizes appropriate testing and imaging with use of ASAS guidelines to provide an accurate diagnosis, while sharing case examples through disease progression and treatment selection.
- Pathogenesis and patient burden of axSpA
- How to diagnose radiographic and nonradiographic ankylosing spondylitis
- Assessing axSpA disease burden and response to treatment
- How to manage treatment progression
- Review of FDA-approved treatments and emerging therapies
- Treat-to-target approach with individualized therapy
This activity is intended for rheumatologists, primary care physicians, nurse practitioners, physician assistants and other healthcare providers who diagnose and manage patients with axial spondyloarthritis.
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Vice Chair of the Department of Rheumatic and Immunologic Diseases
Case Western Reserve University
|Available Credit:||1.00 AMA PRA Category 1 Credit™.|
|Opens:||August 31, 2020|
|Expires:||August 30, 2021|
Primary Care Physicians
Other Healthcare Providers